

1

SUPPLEMENTARY MATERIALS

2

3

4

1. SUPPLEMENTARY FIGURES

5

2. SUPPLEMENTARY TABLES

6

3. SUPPLEMENTARY DATA FILES


7

4. SUPPLEMENTARY ACKNOWLEDGEMENTS

5. Conflict of Interest statement

8 SUPPLEMENTARY FIGURES

9




10

11 **Figure S1. Upper respiratory tract differential expression and host-viral classifier development and evaluation.**

12 **A.** Volcano plot demonstrating the 53 differentially expressed genes between mortality and survival in the upper
 13 respiratory tract in the IMPACC cohort (red = upregulated with mortality, blue = downregulated with mortality), using a
 14 Benjamini-Hochberg adjusted p-value of 0.05. **B.** Violin plots showing the area under the curve (AUC) distribution for
 15 each of the upper respiratory tract classifiers, evaluated in the training cohort. **C.** Boxplots comparing the \log_2 counts
 16 per million normalized gene expression of the three-gene classifier genes (*SLC5A5*, *CD200R1*, *FCER1A*) between
 17 survival (blue) and mortality (red) in the IMPACC upper respiratory tract data set. **D.** Performance of three-gene
 18 classifier with (green) and without (yellow) the addition of age and CT value in the validation cohort. Area under the
 19 curve (AUC) listed as value with 95% confidence interval.

20




21

22 **Figure S2. Performance of combined prognostic classifiers in the IMPACC cohort.** **A.** Receiver operating
23 characteristic (ROC) curve displaying the performance of a combined classifier consisting of OLAH, the three genes
24 from the blood prognostic classifier, age, and SARS-CoV-2 cycle threshold (CT) in the IMPACC peripheral blood data.
25 Area under the curve (AUC) listed as a value with 95% confidence interval. **B.** ROC curve displaying performance of a
26 classifier consisting of OLAH, the three genes from the nasal prognostic classifier, age, and CT.

27


28

29




30

31 **Figure S3. Pathways associated with mortality in the validation cohort.** Gene set enrichment analysis (GSEA)
 32 demonstrating statistically significant pathways based on Benjamini-Hochberg adjusted p-value in the validation cohort
 33 (red = upregulated pathways, blue = downregulated pathways).
 34



35
 36
 37
 38
 39
 40
 41
 42
 43


Figure S4. Performance of classifiers consisting of clinical variables in the IMPACC cohort. Receiver operating characteristic (ROC) curve displaying the performance of classifiers consisting of C-reactive protein (CRP), sepsis-related organ failure assessment score (SOFA) score, baseline respiratory ordinal score (O2 requirement), and absolute lymphocyte count. Area under the curve (AUC) listed as a value with 95% confidence intervals. Analysis was performed on individuals with PBMC RNA-seq data available.



44
45

46 **Figure S5. Performance of a previously published mortality classifier in the IMPACC cohort.** Performance of the
47 Buturovic et al. six gene classifier with (yellow) and without (purple) the added features of age and SARS-CoV-2 cycle
48 threshold in IMPACC. Area under the curve (AUC) listed as value with 95% confidence interval.

SARS-CoV-2 viral load measurement imputation



49

50 **Figure S6. Robust regression for integrating SARS-CoV-2 reads-per-million (RPM) and cycle threshold values.**

51 Scatter plot showing the relationship between $\log(\text{SARS-CoV-2 RPM} + 1)$ and SARS-CoV-2 cycle threshold (CT), for all
52 subjects with both data available ($n = 708$). The line of best fit is based on a robust regression model (adjusted R-
53 squared = 0.693, residual standard error = 2.978). Both the intercept and rpm value were significantly associated with
54 CT value ($P < 2e-16$) based on linear regression.

55

56 **SUPPLEMENTARY TABLES**

57

58

	Survival (n=80)	Mortality (n=42)	P-value
Age, median (IQR)	65.5 (54.0-74.5)	69.5 (58.0-79.0)	0.234
Male, n (%)	48 (60.0%)	28 (66.7%)	0.557
Female, n (%)	32 (40.0%)	14 (33.3%)	0.557
Race, n (%)			0.722
White	34 (42.5%)	13 (31.0%)	
Black/African American	11 (13.8%)	7 (16.7%)	
Asian	22 (27.5%)	14 (33.3%)	
American Indian/Alaska Native	1 (1.3%)	0 (0.0%)	
Unknown	12 (15.0%)	8 (19.0%)	
Hispanic ethnicity, n (%)	9 (11.3%)	6 (14.3%)	0.762
Comorbidities, n (%)			
Diabetes	25 (31.3%)	15 (35.7%)	0.686
Hypertension	31 (38.8%)	14 (33.3%)	0.693
Chronic pulmonary disease	20 (25.0%)	8 (19.0%)	0.505
Cancer	13 (16.3%)	10 (23.8%)	0.337
Immunocompromised	6 (6.5%)	7 (16.7%)	0.133
Autoimmune disease	3 (3.8%)	0 (0.0%)	0.551
Mechanical ventilation, n (%)	65 (81.3%)	35 (83.3%)	0.999
Vasopressor use, n (%)	62 (77.5%)	37 (88.1%)	0.223

59

60

61 **Table S1: Sepsis cohort (EARLI) demographics.** Demographics are stratified by survival status. Race was noted
62 “unknown” if patient declined, was unable to answer, if they selected “other” as an option, or if data were missing. Mann-
63 Whitney test was used for all continuous variables, and Fisher’s exact test was used for all categorical values. IQR,
64 interquartile range; EARLI, Early Assessment of Renal and Lung Injury.

65

Size	Genes	AUC Mean	AUC Std. Dev.
2	ATP1B2, DAAM2	0.79	0.04
3	ATP1B2, DAAM2, CD83	0.80	0.04
4	ATP1B2, DAAM2, TSPAN7, KCNH8	0.81	0.04
5	ATP1B2, DAAM2, TSPAN7, KCNH8, CD83	0.82	0.04
6	ATP1B2, DAAM2, TSPAN7, KCNH8, CD83, FCER1A	0.82	0.04
8	ATP1B2, DAAM2, TSPAN7, KCNH8, CD83, FCER1A, NR4A3, CPA3	0.82	0.05
10	ATP1B2, DAAM2, TSPAN7, KCNH8, CD83, FCER1A, NR4A3, CPA3, TMEM45A, MLNR	0.82	0.04

66

67

68

69

70

Table S2. Peripheral blood candidate mortality classifiers generated by LASSO. The best performing gene sets for feature lengths n = 2-6, 8, and 10 based on the 3-fold random partitioning evaluation of performance characteristics. Bolded genes are the genes included in the final three gene classifier. LASSO, least absolute shrinkage and selection operator; AUC, area under the receiver operating characteristic curve.

71

Length	Genes	AUC mean	AUC Std. Dev
2	SLC5A5, CD200R1	0.79	0.04
3	SLC5A5, CD200R1, FCER1A	0.80	0.04
4	SLC5A5, CD200R1, FCER1A, MARCO	0.80	0.04

72

73

74

75

76

Table S3. Nasal swab candidate mortality classifiers generated by LASSO. The best performing gene sets for feature lengths n = 2-4 based on the 3-fold random partitioning evaluation of performance characteristics. Bolded genes are the genes included in the final three gene classifier. LASSO, least absolute shrinkage and selection operator; AUC, area under the receiver operating characteristic curve.

	Survival (n=116)	Mortality (n=21)	P-value
Age, median (IQR)	56.0 (44.3-70.2)	67.5 (49.9-78.2)	0.052
Male, n (%)	78 (67.2%)	13 (61.9%)	0.625
Female, n (%)	38 (32.8%)	8 (38.1%)	0.625
Race, n (%)			0.391
White	38 (32.8%)	6 (28.6%)	
Black/African American	10 (8.6%)	5 (23.8%)	
Asian	18 (15.5%)	4 (19.0%)	
Native Hawaiian/Pacific Islander	2 (1.7%)	0 (0.0%)	
American Indian/Alaska Native	1 (0.9%)	0 (0.0%)	
Unknown	47 (40.5%)	6 (28.6%)	
Hispanic ethnicity, n (%)	48 (41.4%)	8 (38.1%)	0.815
Comorbidities, n (%)			
BMI > 30	51 (44.0%)	10 (47.6%)	0.814
HIV	3 (2.6%)	1 (4.8%)	0.490
Rheumatologic disorder	15 (12.9%)	2 (9.5%)	0.999
Solid organ transplant	17 (14.7%)	2 (9.5%)	0.737
Mechanical ventilation, n (%)	34 (29.3%)	16 (76.2%)	<0.001
Steroid use, n (%)	59 (50.9%)	17 (81.0%)	0.016
Vaccinated for COVID-19, n (%)	45 (38.8%)	10 (47.6%)	0.476

78

79

80

81

82

83

84

Table S4: COVID-19 external validation cohort (COMET) demographics. Demographics are stratified by survival status. Race was noted “unknown” if patient declined, was unable to answer, if they selected “other” as an option, or if data were missing. Mann-Whitney test was used for all continuous variables, and Fisher’s exact test was used for all categorical values. IQR, interquartile range; BMI, body mass index; COMET, COVID-19 Multi-immunophenotyping projects for Effective Therapies.

SOFA classifier	AUC (95% CI)	Comparison classifier	AUC (95% CI)	DeLong P-value
SOFA	0.67 (0.51 - 0.80)	Three genes + Age + CT (PBMC)	0.88 (0.82 - 0.94)	0.003
SOFA	0.67 (0.51 - 0.80)	OLAH + Age + CT (PBMC)	0.86 (0.79 - 0.93)	0.010
SOFA	0.73 (0.61 - 0.83)	Three genes + Age + CT (NS)	0.74(0.64 - 0.83)	0.400
SOFA	0.73 (0.61 - 0.83)	OLAH + Age + CT (NS)	0.78 (0.69 - 0.86)	0.064

85

86 **Table S5: Comparison between performance of a prognostic model based on Sepsis-related Organ Failure**
87 **Assessment (SOFA) score and parsimonious classifiers.** Performance is based on analysis in the respective cohort
88 (PBMC or NS). Significance between the area under the curve (AUC) values was determined based on the paired
89 DeLong test. PBMC, peripheral blood mononuclear cell; NS, nasal swab.

90

91

Model	Feature	Coefficients
PBMC 3 gene + age + CT	<i>CD83</i>	-0.52
	<i>ATP1B2</i>	0.54
	<i>DAAM2</i>	0.45
	Age	0.66
	CT	-0.28
PBMC <i>OLAH</i> + age + CT	<i>OLAH</i>	0.42
	Age	0.68
	CT	-0.30
NS 3 gene + age + CT	<i>SLC5A5</i>	0.57
	<i>CD200R1</i>	-0.51
	<i>FCER1A</i>	0.47
	Age	0.75
	CT	-0.25
NS <i>OLAH</i> + age + CT	<i>OLAH</i>	0.44
	Age	0.82
	CT	-0.36

92
93
94
95
96
97

Table S6. Model coefficients for features for the four main models discussed in the main manuscript. Each model consisted of a combination of genes, age, and SARS-CoV-2 cycle threshold value. Coefficients are generalized linear model coefficients with a logistic regression binary task. PBMC, peripheral blood mononuclear cell; CT, cycle threshold.

98 **SUPPLEMENTARY DATA FILES**

99

100 **Supplementary Data File 1. A.** Genes differentially expressed with mortality in IMPACC blood
101 samples (n=785), adjusted for age and sex. **B.** Gene set enrichment analysis (GSEA) of
102 differentially expressed genes. Legend: logFC = log(2) fold change; padj = Benjamini-Hochberg
103 adjusted P value; NES = normalized enrichment score; size = size of Reactome pathway;
104 LeadingEdge = leading edge genes.

105

106 **Supplementary Data File 2. A.** Genes differentially expressed with mortality in IMPACC upper
107 respiratory tract samples (n=842), adjusted for age and sex . **B.** Gene set enrichment analysis
108 (GSEA) of differentially expressed genes. Legend: logFC = log(2) fold change; padj =
109 Benjamini-Hochberg adjusted P value; NES = normalized enrichment score; size = size of
110 Reactome pathway; LeadingEdge = leading edge genes.

111

112 **Supplementary Data File 3. A.** Genes differentially expressed with mortality in EARLI blood
113 samples (n=122), adjusted for age and sex. **B.** Gene set enrichment analysis (GSEA) of
114 differentially expressed genes. Legend: logFC = log(2) fold change; padj = Benjamini-Hochberg
115 adjusted P value; NES = normalized enrichment score; size = size of Reactome pathway.

116

117 **Supplementary Data File 4. A.** Genes differentially expressed with mortality in COMET blood
118 samples (n=137), adjusted for age and sex. **B.** Gene set enrichment analysis (GSEA) of
119 differentially expressed genes. Legend: logFC = log(2) fold change; padj = Benjamini-Hochberg
120 adjusted P value; NES = normalized enrichment score; size = size of Reactome pathway;
121 LeadingEdge = leading edge genes.

122

123 **SUPPLEMENTARY ACKNOWLEDGEMENTS**

124

125 **A. IMPACC Network Consortium**

126 Elaine F. Reed, Joanna Schaenman, Ramin Salehi-rad, Adreanne M. Rivera, Harry Pickering,
127 Subha Sen, David Elashoff, Dawn C. Ward, Jenny Brook, Estefania Ramires-Sanchez, Megan
128 Llamas, Claudia Perdomo, Clara E. Magyar, Jennifer Fulcher, David J. Erle, Carolyn S. Calfee,
129 Carolyn M. Hendrickson, Kirsten N. Kangelaris, Viet Nguyen, Deanna Lee, Suzanna Chak, Rajani
130 Ghale, Ana Gonzalez, Alejandra Jauregui, Carolyn Leroux, Luz Torres Altamirano, Ahmad Sadeed
131 Rashid, Andrew Willmore, Prescott G. Woodruff, Matthew F. Krummel, Sidney Carrillo, Alyssa
132 Ward, Charles R. Langelier, Ravi Patel, Michael Wilson, Ravi Dandekar, Bonny Alvarenga, Jayant
133 Rajan, Walter Eckalbar, Andrew W. Schroeder, Gabriela K. Fragiadakis, Alexandra Tsitsiklis, Eran
134 Mick, Yanedth Sanchez Guerrero, Christina Love, Lenka Maliskova, Michael Adkisson,
135 Aleksandra Leligdowicz, Alexander Beagle, Arjun Rao, Austin Sigman, Bushra Samad, Cindy
136 Curiel, Cole Shaw, Gayelan Tietje-Ulrich, Jeff Milush, Jonathan Singer, Joshua J. Vasquez, Kevin
137 Tang, Legna Betancourt, Lekshmi Santhosh, Logan Pierce, Maria Tecero Paz, Michael M.
138 Matthay, Neeta Thakur, Nicklaus Rodriguez, Nicole Sutter, Norman Jones, Pratik Sinha, Priya
139 Prasad, Raphael Lota, Sadeed Rashid, Saurabh Asthana, Sharvari Bhide, Tasha Lea, Yumiko
140 Abe-Jones, Lauren I. R. Ehrlich, Esther Melamed, Cole Maguire, Dennis Wylie, Justin F.
141 Rousseau, Kerin C. Hurley, Janelle N. Geltman, Nadia Siles, Jacob E. Rogers, Pablo Guaman
142 Tipan, Nadine Roupheal, Steven E. Bosinger, Arun K. Boddapati, Greg K. Tharp, Kathryn L.
143 Pellegrini, Brandi Johnson, Bernadine Panganiban, Christopher Huerta, Evan J. Anderson, Hady
144 Samaha, Jonathan E. Sevransky, Laurel Bristow, Elizabeth Beagle, David Cowan, Sydney
145 Hamilton, Thomas Hodder, Amer Bechnak, Andrew Cheng, Aneesh Mehta, Caroline R. Ciric,
146 Christine Spainhour, Erin Carter, Erin M. Scherer, Jacob Usher, Kieffer Hellmeister, Laila Hussaini,
147 Lauren Hewitt, Nina Mcnair, Susan Pereira Ribeiro, Sonia Wimalasena, Jordan P. Metcalf, Nelson
148 I. Agudelo Higueta, Lauren A. Sinko, J. Leland Booth, Douglas A. Drevets, Brent R. Brown, Mark
149 A. Atkinson, Scott C. Brakenridge, Ricardo F. Ungaro, Brittany Roth Manning, Lyle Moldawer,
150 William B. Messer, Catherine L. Hough, Sarah A. R. Siegel, Peter E. Sullivan, Zhengchun Lu,
151 Amanda E. Brunton, Matthew Strand, Zoe L. Lyski, Felicity J. Coulter, Courtney Micheletti,
152 Matthew C. Altman, Naresh Doni Jayavelu, Scott Presnell, Bernard Kohr, Tomasz Jancsyk, Azlann
153 Arnett, Patrice M. Becker, Alison D. Augustine, Steven M. Holland, Lindsey B. Rosen, Serena
154 Lee, Tatyana Vaysman, Al Ozonoff, Joann Diray-Arce, Jing Chen, Alvin T. Kho, Carly E. Milliren,
155 Annmarie Hoch, Ana C. Chang, Kerry McEnaney, Caitlin Syphurs, Brenda Barton, Claudia
156 Lentucci, Maimouna D. Murphy, Mehmet Saluvan, Tanzia Shaheen, Shanshan Liu, Marisa Albert,
157 Arash Nemati Hayati, Robert Bryant, James Abraham, Mitchell Cooney, Meagan Karoly, Ofer
158 Levy, Hanno Steen, Patrick van Zalm, Benoit Fatou, Kinga K. Smolen, Arthur Viode, Simon van
159 Haren, Meenakshi Jha, David Stevenson, Sanya Thomas, Boryana Petrova, Naama Kanarek,
160 Ana Fernandez-Sesma, Viviana Simon, Florian Krammer, Harm Van Bakel, Seunghee Kim-
161 Schulze, Ana Silvia Gonzalez-Reiche, Jingjing Qi, Brian Lee, Juan Manuel Carreño, Gagandeep
162 Singh, Ariel Raskin, Johnstone Tcheou, Zain Khalil, Adriana van de Guchte, Keith Farrugia, Zenab
163 Khan, Geoffrey Kelly, Komal Srivastava, Lily Q. Eaker, Maria C. Bermúdez-González, Lubbertus
164 C. F. Mulder, Katherine F. Beach, Miti Saksena, Deena Altman, Erna Kojic, Levy A. Sominsky,

165 Arman Azad, Dominika Bielak, Hisaaki Kawabata, Temima Yellin, Miriam Fried, Leeba Sullivan,
166 Sara Morris, Giulio Kleiner, Daniel Stadlbauer, Jayeeta Dutta, Hui Xie, Manishkumar Patel, Kai
167 Nie, Brian Monahan, David A. Hafler, Ruth R. Montgomery, Albert C. Shaw, Steven H. Kleinstein,
168 Jeremy P. Gygi, Dylan Duchen, Shrikant Pawar, Anna Konstorum, Ernie Chen, Chris Cotsapas,
169 Xiaomei Wang, Charles Dela Cruz, Akiko Iwasaki, Subhasis Mohanty, Allison Nelson, Yujiao
170 Zhao, Shelli Farhadian, Hiromitsu Asashima, Omkar Chaudhary, Andreas Coppi, John Fournier,
171 M. Catherine Muenker, Khadir Raddassi, Michael Rainone, William Ruff, Syim Salahuddin, Wade
172 L. Shulz, Pavithra Vijayakumar, Haowei Wang, Esio Wunder Jr., H. Patrick Young, Albert I. Ko,
173 Gisela Gabernet, Denise Esserman, Leying Guan, Anderson Brito, Jessica Rothman, Nathan D.
174 Grubaugh, Kexin Wang, Leqi Xu, Holden Maecker, Bali Pulendran, Kari C. Nadeau, Yael
175 Rosenberg-Hasson, Michael Leipold, Natalia Sigal, Angela Rogers, Andrea Fernandes, Monali
176 Manohar, Evan Do, Iris Chang, Alexandra S. Lee, Catherine Blish, Henna Naz Din, Jonasel
177 Roque, Linda N. Geng, Maja Artandi, Mark M. Davis, Neera Ahuja, Samuel S. Yang, Sharon
178 Chinthrajah, Thomas Hagan, Tyson H. Holmes, Koji Abe, Lindsey R. Baden, Kevin Mendez,
179 Jessica Lasky-Su, Alexandra Tong, Rebecca Rooks, Michael Desjardins, Amy C. Sherman,
180 Stephen R. Walsh, Xhoi Mitre, Jessica Cauley, Xiaofang Li, Bethany Evans, Christina Montesano,
181 Jose Humberto Licon, Jonathan Krauss, Nicholas C. Issa, Jun Bai Park Chang, Natalie Izaguirre,
182 David B. Corry, Farrah Kheradmand, Li-Zhen Song, Ebony Nelson, Monica Kraft, Chris Bime,
183 Jarrod Mosier, Heidi Erickson, Ron Schunk, Hiroki Kimura, Michelle Conway, Dave Francisco,
184 Allyson Molzahn, Connie Cathleen Wilson, Ron Schunk, Trina Hughes, Bianca Sierra, Jordan
185 Oberhaus, Faheem W. Guirgis, Brittney Borresen, Matthew L. Anderson, Bjoern Peters, James
186 A. Overton, Randi Vita, Kerstin Westendorf, Scott J. Tebbutt, Casey P. Shannon, Rafick-Pierre
187 Sekaly, Slim Fourati, Grace A. McComsey, Paul Harris, Scott Sieg, George Yendewa, Mary
188 Consolo, Heather Tribout, Susan Pereira Ribeiro, Charles B. Cairns, Elias K. Haddad, Michele A.
189 Kutzler, Mariana Bernui, Gina Cusimano, Jennifer Connors, Kyra Woloszczuk, David Joyner,
190 Carolyn Edwards, Edward Lee, Edward Lin, Nataliya Melnyk, Debra L. Powell, James N. Kim, I.
191 Michael Goonewardene, Brent Simmons, Cecilia M. Smith, Mark Martens, Brett Croen, Nicholas
192 C. Semenza, Mathew R. Bell, Sara Furukawa, Renee McLin, George P. Tegos, Brandon
193 Rogowski, Nathan Mege, Kristen Ullring, Pam Schearer, Judie Sheidy, Crystal Nagle, James A.
194 Overton, Scott R. Hutton, Greg Michelotti, Kari Wong, Adeeb Rahman & Vicki Seyfert-Margolis.

195

196 **B. COMET Consortium**

197 K. Mark Ansel, Stephanie Christenson, Michael Adkisson, Walter Eckalbar, Lenka Maliskova,
198 Andrew Schroeder, Raymund Bueno, Gracie Gordon, George Hartoularos, Divya Kushnoor,
199 David Lee, Elizabeth McCarthy, Anton Ogorodnikov, Matthew Spitzer, Kamir Hiam, Yun S. Song,
200 Yang Sun, Erden Tumurbaatar, Monique van der Wijst, Alexander Whatley, Chayse Jones,
201 Saharai Caldera, Catherine DeVoe, Paula Hayakawa Serpa, Christina Love, Eran Mick, Maira
202 Phelps, Alexandra Tsitsiklis, Carolyn Leroux, Sadeed Rashid, Nicklaus Rodriguez, Kevin Tang,
203 Luz Torres Altamirano, Aleksandra Leligdowicz, Michael Matthay, Michael Wilson, Jimmie Ye,
204 Suzanna Chak, Rajani Ghale, Alejandra Jauregui, Deanna Lee, Viet Nguyen, Austin Sigman,
205 Kirsten N. Kangelaris, Saurabh Asthana, Zachary Collins, Ravi Patel, Arjun Rao, Bushra Samad,
206 Cole Shaw, Andrew Willmore, Tasha Lea, Gabriela K. Fragiadakis, Carolyn S. Calfee, David J.

207 Erle, Carolyn M. Hendrickson, Matthew F. Krummel, Charles R. Langelier, Prescott G. Woodruff,
208 Sidney C. Haller, Alyssa Ward, Norman Jones, Jeff Milush, Vincent Chan, Nayvin Chew, Alexis
209 Combes, Tristan Courau, Kenneth Hu, Billy Huang, Nitasha Kumar, Salman Mahboob, Priscila
210 Muñoz-Sandoval, Randy Parada, Gabriella Reeder, Alan Shen, Jessica Tsui, Shoshana Zha &
211 Wandi S. Zhu.

212

213 **C. EARLI Consortium**

214 Narges Alipanah-Lechner, Kim Bardillon, Carolyn S. Calfee, Suzanna Chak, Olivia Chao
215 Sidney A. Carrillo, Taarini Hariharan, Carolyn M. Hendrickson, Charles R Langelier, Deanna
216 Lee, Carolyn Leroux, Chelsea Lin, Michael A. Matthay, Lucile P. A. Neyton, Angelika Ringor,
217 Aartik Sarma, Emma Schmiede, Natasha Spottiswoode, Kathryn M. Sullivan, Melanie F
218 Weingart, Andrew Willmore, Hanjing Zhuo.

Conflict of interest: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines influenza virus vaccines, and influenza virus therapeutics which list FK as coinventor and he has received royalty payments from some of these patents, US Patents 20250228929A1, 20250186578A1, and 20250041402A1. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, Castlevax, to develop SARS-CoV-2 vaccines, and FK is cofounder and scientific advisory board member. FK has consulted for Merck, GSK, Sanofi, Curevac, Seqirus, and Pfizer and is currently consulting for 3rd Rock Ventures, Gritstone and Avimex, as well as collaborating with Dynavax on influenza vaccine development and with VIR on influenza virus therapeutics. OL is a named inventor on US patents 12268739 and 11730810 held by Boston Children's Hospital relating to vaccine adjuvants and human in vitro platforms that model vaccine action. His laboratory has received research support from GlaxoSmithKline (GSK), where he is a consultant. He is also a cofounder of and advisor to ARMR Sciences. CBC serves as a consultant to bioMerieux and is funded for a grant from Bill & Melinda Gates Foundation. JAO is a consultant at Knocean Inc. JLS serves as a scientific advisor of Precion Inc. SRH, GM, and KW are employees of Metabolon Inc. VSM is a current employee of MyOwnMed. NR reports grants or contracts with Merck, Sanofi, Pfizer, Vaccine Company, Quidel, Lilly, and Immorna and has participated on data safety monitoring boards for Moderna, Sanofi, Seqirus, Pfizer, EMMES, ICON, BARDA, Imunon, CyanVac, and Micron. NR has also received support for meetings/travel from Sanofi and Moderna and honoraria from Virology Education.